Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19274086 | TOPICAL FORMULATION FOR A JAK INHIBITOR | July 2025 | January 2026 | Allow | 6 | 0 | 0 | Yes | No |
| 19212445 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERI-IMPLANTITIS AND PERIODONTITIS | May 2025 | August 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19171214 | TOPICAL FORMULATION FOR JAK INHIBITOR | April 2025 | October 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19060423 | FAST ABSORBING TROLAMINE SALICYLATE FORMULATIONS AND COMPOSITIONS | February 2025 | October 2025 | Allow | 7 | 0 | 1 | Yes | No |
| 19016312 | READY-TO-USE NON-AQUEOUS ORAL SOLUTION OF LOSARTAN | January 2025 | August 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18974530 | Preparation Method and Application of Micelle Preparation Containing Thymol and Derivative Thereof | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18941896 | Progestin/Testosterone Transdermal Gel | November 2024 | August 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 18934749 | STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTS | November 2024 | November 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18884931 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | September 2024 | August 2025 | Abandon | 11 | 1 | 0 | Yes | No |
| 18814130 | PHARMACEUTICAL RECTAL SUPPOSITORY COMPOSITIONS OF 6-THIOGUANINE, METHODS OF TREATMENT AND/OR METHODS OF MANUFACTURING | August 2024 | January 2026 | Allow | 17 | 2 | 1 | Yes | No |
| 18794128 | AMLODIPINE FORMULATIONS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | No | No |
| 18768656 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | July 2024 | August 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18659957 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES | May 2024 | December 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18638564 | SYSTEMS AND METHODS FOR DELIVERY OF PHENYLALANINE AND LACTATE | April 2024 | October 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18600419 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | March 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18600431 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | March 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18590910 | ANALGESIC AND ANTIPRURITIC PHARMACERTICAL COMPOSITION AND APPLICATION THEREOF | February 2024 | February 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18588626 | TOPICAL FORMULATION FOR A JAK INHIBITOR | February 2024 | December 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18441397 | STABLE PHARMACEUTICAL COMPOSITIONS OF CYCLOPHOSPHAMIDE | February 2024 | January 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18528684 | STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDE | December 2023 | August 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18526030 | METHOD FOR IMPROVING THE SENSORIAL PROPERTIES OF OIL-IN-WATER EMULSIONS, TO REDUCE THE ADHESIVE EFFECT OF SUCH GLYCERIN-BASED OIL-IN-WATER EMULSIONS | December 2023 | February 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18515184 | PROCESS FOR OBTAINING A PURIFIED PSYCHOACTIVE ALKALOID SOLUTION | November 2023 | February 2026 | Abandon | 27 | 3 | 1 | No | No |
| 18487671 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION | October 2023 | April 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18374860 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | September 2023 | October 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18478029 | AR+BREAST CANCER TREATMENT METHODS | September 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18455759 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | August 2023 | September 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18455242 | TOPICAL DETOMIDINE FORMULATIONS | August 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18221164 | PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CHANGES TO THE RECTUM | July 2023 | August 2025 | Allow | 26 | 2 | 0 | Yes | Yes |
| 18345692 | Method and Formulation for Improving Roflumilast Skin Penetration Lag Time | June 2023 | August 2025 | Abandon | 26 | 3 | 0 | Yes | No |
| 18345732 | Method and Formulation for Improving Roflumilast Skin Penetration Lag Time | June 2023 | August 2025 | Abandon | 26 | 4 | 0 | Yes | No |
| 18339206 | METHOD FOR TREATING INFECTIONS | June 2023 | December 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18334084 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR DOWNSTREAM EFFECTORS - INDUCED CUTANEOUS REACTIONS | June 2023 | May 2025 | Abandon | 24 | 3 | 1 | No | No |
| 18123828 | TOPICAL COMPOSITION | March 2023 | September 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18024943 | ANTICOCCIDIAL COMPOSITION COMPRISING COUMARIC ACID AND USE THEREOF | March 2023 | February 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18176296 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | February 2023 | February 2026 | Abandon | 35 | 4 | 0 | No | Yes |
| 18174706 | DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACIDS | February 2023 | September 2025 | Allow | 31 | 5 | 0 | Yes | No |
| 18022886 | Nano-Emulsion Based Compositions, Methods for Their Preparation and Their Use in Delivery of Active Ingredients | February 2023 | January 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18096165 | COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN | January 2023 | October 2025 | Abandon | 33 | 3 | 0 | No | No |
| 18077296 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS | December 2022 | December 2024 | Allow | 24 | 1 | 0 | No | No |
| 17925382 | SOLID LIPID NANO-COMPOSITION CONTAINING BERBERINE AND CINNAMONALDEHYDE EFFECTIVE IN TREATING DIABETES, DYSLIPIDEMIA, AND METHOD OF PREPARING THE SAME | November 2022 | January 2026 | Allow | 38 | 1 | 0 | Yes | No |
| 17921865 | LIQUID FORMULATION AND PHARMACEUTICAL PRODUCT CONTAINING CILASTATIN | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17959069 | SYSTEMS AND METHODS FOR DELIVERY OF N-LACTOYL-PHENYLALANINE AND OTHER N-LACTOYL-AMINO ACIDS | October 2022 | August 2025 | Abandon | 34 | 6 | 1 | No | No |
| 17942505 | PHARMACEUTICAL COMPOSITION CONTAINING B-LAPACHONE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CHOLESTATIC LIVER DISEASE | September 2022 | May 2024 | Allow | 20 | 3 | 0 | Yes | No |
| 17820783 | METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE | August 2022 | April 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17887798 | SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHER | August 2022 | January 2026 | Abandon | 41 | 3 | 0 | Yes | No |
| 17887826 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | August 2022 | July 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17877602 | USE OF NICOLSAMIDE FORMULATIONS FOR ANTIVIRAL THERAPY | July 2022 | March 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17758783 | COMPOSITIONS COMPRISING DESOXIMETASONE AND TAZAROTENE | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17789907 | APREPITANT FOR USE IN THE TOPICAL TREATMENT OF FACIAL NEURALGIA | June 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17847205 | TOPICAL PHARMACEUTICAL FORMULATION | June 2022 | September 2025 | Allow | 39 | 3 | 0 | Yes | No |
| 17787187 | TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATING ONYCHOMYCOSIS | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17840502 | VAPORIZABLE PSYCHOACTIVE ALKALOID COMPOSITION AND PREPARATION THEREOF | June 2022 | November 2024 | Abandon | 29 | 4 | 1 | No | No |
| 17782996 | ORALLY DISSOLVING FORMULATIONS OF PRUCALOPRIDE | June 2022 | February 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17804342 | TOPICAL TREATMENT FOR ANORECTAL DISORDERS WITH AND WITHOUT SEAT CUSHION | May 2022 | June 2025 | Abandon | 37 | 4 | 1 | Yes | No |
| 17738422 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | May 2022 | September 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17773091 | IMPROVING RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION | April 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17771122 | TREATMENT OF INFLAMMATORY CONDITION IN MUCOUS MEMBRANE OR SKIN | April 2022 | October 2025 | Allow | 42 | 0 | 1 | Yes | No |
| 17724262 | PHARMACEUTICAL COMPOSITION CONTAINING B-LAPACHONE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CHOLESTATIC LIVER DISEASE | April 2022 | November 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17770276 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA1A-AR PARTIAL AGONISTS | April 2022 | February 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17713082 | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES | April 2022 | March 2025 | Abandon | 35 | 3 | 1 | No | No |
| 17703543 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | March 2022 | July 2023 | Allow | 16 | 6 | 1 | Yes | No |
| 17642136 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | March 2022 | April 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17636917 | FORMULATIONS FOR USE IN THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES | February 2022 | October 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17673518 | USING FATTY ACID SYNTHASE INHIBITORS TO TREAT FIBROSIS | February 2022 | November 2024 | Allow | 33 | 2 | 1 | Yes | Yes |
| 17591223 | METHODS AND COMPOSITIONS TO PREVENT AND TREAT DISORDERS ASSOCIATED WITH MUTATIONS IN THE ODC1 GENE | February 2022 | August 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17630775 | PROCESS FOR THE PREPARATION OF TOPICAL FORMULATION | January 2022 | January 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17629424 | TOPICAL JAK INHIBITOR COMBINATION COMPOSITIONS FOR TREATMENT OF INFLAMMATORY SKIN CONDITIONS | January 2022 | November 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17627692 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | January 2022 | January 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17624188 | IBUPROFEN ESTER DERIVATIVE AND EMULSION PREPARATION THEREOF | December 2021 | January 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17621330 | CBD COMPOSITION | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17554316 | TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF | December 2021 | March 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17541439 | TOPICAL FORMULATION FOR A JAK INHIBITOR | December 2021 | January 2026 | Allow | 49 | 2 | 1 | No | No |
| 17614647 | PYRIMIDINE DERIVATIVE INHIBITING GROWTH OF CANCER CELL AND MEDICINAL USE THEREOF | November 2021 | September 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17496460 | METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION | October 2021 | May 2025 | Abandon | 43 | 5 | 0 | Yes | Yes |
| 17449785 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | October 2021 | March 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17440778 | TREATMENT OF ROSACEA WITH TOPICAL COMBINATION COMPOSITIONS | September 2021 | July 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17293903 | BIASED NMDA RECEPTOR MODULATORS AND USES THEREOF | May 2021 | July 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17292027 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | May 2021 | January 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17271261 | ACRYLATE-FREE COSMETIC EMULSION | February 2021 | September 2025 | Allow | 55 | 2 | 1 | Yes | No |
| 17165652 | METHODS OF TREATING EPITHELIOID CELL TUMORS | February 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17153611 | TOPICAL DETOMIDINE FORMULATIONS | January 2021 | April 2025 | Abandon | 51 | 5 | 1 | Yes | No |
| 17052775 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | November 2020 | September 2024 | Allow | 47 | 4 | 0 | Yes | No |
| 17087365 | METHODS OF INDUCING ANESTHESIA | November 2020 | March 2025 | Abandon | 53 | 2 | 1 | Yes | Yes |
| 16971472 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | August 2020 | June 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 16932352 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | July 2020 | September 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16766019 | RHEOLOGY ADDITIVES BASED ON DI-OR TRI-AMIDES AND MIXTURES THEREOF | May 2020 | February 2024 | Allow | 45 | 5 | 1 | Yes | No |
| 16809662 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | March 2020 | November 2024 | Abandon | 56 | 4 | 1 | Yes | No |
| 16470350 | METHOD FOR IMPROVING THE SENSORIAL PROPERTIES OF OIL-IN-WATER EMULSIONS, TO REDUCE THE ADHESIVE EFFECT OF SUCH GLYCERIN-BASED OIL-IN-WATER EMULSIONS | June 2019 | February 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16365364 | USE OF TIOTROPIUM BROMIDE TO PREVENT PULMONARY OXYGEN TOXICITY | March 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16246320 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | January 2019 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 15757266 | METHODS FOR TREATMENT OF MONOCYTE DYSFUNCTION AND CHRONIC INFLAMMATORY MICRO AND MACRO-VASCULAR DISEASES | March 2018 | March 2026 | Abandon | 60 | 10 | 1 | Yes | No |
| 15528882 | TREATMENT OF SKIN ATROPHY WITH A COMBINATION OF TRIIODOTHYROACETIC ACID (TRIAC) AND DEHYDROEPIANDROSTERONE (DHEA) | May 2017 | December 2018 | Allow | 19 | 1 | 1 | Yes | No |
| 15229116 | Therapeutic Calcium Phosphate Particles in Use for Aesthetic or Cosmetic Medicine, and Methods of Manufacture and Use | August 2016 | February 2020 | Allow | 42 | 3 | 1 | Yes | No |
| 15226415 | Formulations that Provide Support During Vaccinations and Adaptive Immune System Response | August 2016 | December 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 15220617 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | July 2016 | April 2019 | Allow | 33 | 2 | 1 | Yes | Yes |
| 14971230 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | December 2015 | April 2018 | Allow | 28 | 2 | 1 | No | No |
| 14704375 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL OR A NEBIVOLOL ANALOGUE | May 2015 | June 2018 | Allow | 38 | 4 | 1 | Yes | No |
| 14612143 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS | February 2015 | August 2015 | Allow | 7 | 1 | 1 | Yes | No |
| 14499457 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION | September 2014 | February 2016 | Allow | 17 | 0 | 0 | Yes | No |
| 14453861 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION | August 2014 | February 2016 | Allow | 18 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SOROUSH, LAYLA.
With a 62.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 52.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SOROUSH, LAYLA works in Art Unit 1622 and has examined 107 patent applications in our dataset. With an allowance rate of 90.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner SOROUSH, LAYLA's allowance rate of 90.7% places them in the 74% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SOROUSH, LAYLA receive 2.79 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SOROUSH, LAYLA is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +4.6% benefit to allowance rate for applications examined by SOROUSH, LAYLA. This interview benefit is in the 29% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 17.0% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 58.1% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.5% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.2% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 14.0% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.